ImpediMed Stock

ImpediMed EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of ImpediMed (IPD.AX) as of Aug 12, 2026 is -55.23 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -45.17 % — a change of 22.27% (lower).

EBIT/Assets

-55.23 %

YoY

22.27%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of ImpediMed is 2026 -55.23 % . Operating Income to Assets Ratio (EBIT/Assets) of ImpediMed was 2025 -45.17 % . It decreases by 22.27% lower compared to the previous year.
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Operating Income to Assets Ratio (EBIT/Assets) of ImpediMed is -55.23 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of ImpediMed changed from -45.17 % to -55.23 %, representing a 22.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — ImpediMed

All Key Metrics — ImpediMed